Navigation Links
Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract and Increase Funding for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
Date:10/1/2013

SAN DIEGO, Oct. 1, 2013 /PRNewswire/ -- Pfenex Inc. today announced that the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA), has modified its prime contract and simultaneously exercised an option associated with the existing Pfenex contractual relationship begun in July, 2010. This extends the prime contract and increases the funding to support the development of a next generation rPA-based anthrax vaccine based on rPA produced in its platform technology, Pfēnex Expression Technology™.  The increase in funding of approximately $8.0 million brings the total funding available to approximately $23.9 million over the course of the contract if all options are exercised. During the contract's base period, Pfenex demonstrated that a strongly immunogenic, stable and protective form of rPA could be expressed and recovered from the highly efficient fermentation of a strain of P. fluorescens engineered to produce rPAThe exercise of this option allows for the completion of preclinical studies, implementation of analytical methods and cGMP manufacturing.

"We are pleased with the results and progress provided by Pfenex's recombinant platform technology to the production of a next generation anthrax vaccine," stated Bertrand C. Liang, Chief Executive Officer. "The exercise of this option and increase in funding by BARDA enables Pfenex and BARDA to continue our successful partnership sharing a common objective to develop an anthrax vaccine with a process capable of achieving the goals of the Strategic National Stockpile for the U. S. Government, including production, shelf life, and administration improvements."

About Pfenex Inc.  
Pfenex Inc. is a biotechnology company developing biosimilars and innovative vaccines to address unmet and growing global healthcare needs.  Utilizing the company's core technology, Pfēnex Expression Technology™ for recombinant protein expression, Pfenex is able to rapidly develop and produce high quality biopharmaceuticals. In addition, Pfenex also produces and markets research proteins and reagent proteins for the research and drug development community through its Reagent Proteins division.  For more information please visit www.pfenex.com 


'/>"/>
SOURCE Pfenex Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Nuisance seaweed found to produce compounds with biomedical potential
2. MADRID-MIT M+Vision Consortium hosts Biomedical Innovation Conference 2012
3. UMass Medical School scientist named 2012 Pew Latin-American Fellow in the Biomedical Sciences
4. 22 of Americas most promising scientists selected as Pew Biomedical Scholars
5. Top young Latin-American scientists named Pew Biomedical Fellows
6. Saladax Biomedical Enters into Master Collaboration Agreement with Bristol-Myers Squibb
7. BGI Tech and BAB jointly develop transgenic mice platform for biomedical research
8. Reproducibility Initiative to increase the value of biomedical research
9. £30 million boost for biomedical engineering research
10. MU celebrates $5 million partnership for advancing biomedical discoveries
11. CNIO participates in the ENCODE project: A stride forward in biomedical research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2020)... PENSACOLA, Fla. (PRWEB) , ... August 05, 2020 , ... ... to cover two new innovations, CoreText™ and ProText™, making them the first Wharton’s jelly ... a defect using a syringe. The company’s solutions are the first Wharton’s jelly allograft ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study has ... Invictus Medical Neoasis™ active noise control device to attenuate typical noises in a ... device attenuated the alarm sounds from patient monitors, ventilators and other bedside devices ...
(Date:7/2/2020)... ... July 01, 2020 , ... ... phase 1a findings of Neihulizumab, a biologic for the treatment of steroid-refractory acute ... Led by hemato-oncologist Dr. Paul J Martin of the Fred Hutchinson Cancer Research ...
Breaking Biology News(10 mins):
(Date:8/3/2020)... LEXINGTON, Ky. (PRWEB) , ... August 03, 2020 , ... ... innovative products for transformative growth, , Known as MediVet Biologics ... Health brand. , The new Ardent Animal Health will build on its ...
(Date:7/31/2020)... ... 29, 2020 , ... Diversified Technologies, Inc. has introduced a ... to drive Klystrons, TWTs, IOTs, and magnetrons. , DTI Radar Transmitter Systems ... a push-pull configuration; yielding fast fall time for a capacitive load. These all ...
(Date:7/31/2020)... ... ... eSource has long been touted as the solution to high data management and ... it did not take off as quickly as people initially expected, and where eSource ... capturing data electronically for clinical trials and then repurposing it for downstream analysis, at ...
(Date:7/22/2020)... ... ... Join experts from Reed Tech , Gary Saner, Sr. Manager, Information ... live webinar on Thursday, August 13, 2020 at 11am EDT (4pm BST/UK). ... Specifically, for medical devices, the NMPA has departments dealing with medical device registration (pre-market ...
Breaking Biology Technology: